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Abstract
Background: Systemic telomere length has been associated with measures of
diastolic function, vascular stiffness and left ventricular mass mainly in smaller,
patient-specific settings and not in a general population. In this study we describe
the applicability of these findings in a large, representative population.
Methods and Results: Peripheral blood leukocyte telomere length (PBL TL) was
measured using telomere restriction fragment analysis in the young to middle-aged
(.2500 volunteers, ,35 to 55 years old) Asklepios study population, free from
overt cardiovascular disease. Subjects underwent extensive echocardiographic,
hemodynamic and biochemical phenotyping. After adjusting for relevant
confounders (age, sex, systolic blood pressure, heart rate, body mass index and
use of antihypertensive drugs) we found no associations between PBL TL and left
ventricular mass index (P50.943), ejection fraction (P50.933), peak systolic septal
annular motion (P50.238), pulse wave velocity (P50.971) or pulse pressure
(P50.999). In contrast, our data showed positive associations between PBLTL and
parameters of LV filling: the transmitral flow early (E) to late (A) velocity ratio (E/A-
ratio; P,0.001), the ratio of early (e9) to late (a9) mitral annular velocities (e9/a9-ratio;
P50.012) and isovolumic relaxation time (P50.015). Interestingly, these
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associations were stronger in women than in men and were driven by associations
between PBL TL and the late diastolic components (A and a9).
Conclusions: In a generally healthy, young to middle-aged population, PBL TL is
not related to LV mass or systolic function, but might be associated with an altered
LV filling pattern, especially in women.
Introduction
The progression of acquired cardiovascular diseases (CVD) throughout the
human life can typically be tracked by a series of gradual changes in physical,
chemical and biological parameters. Levels of systolic blood pressure (SBP),
cholesterol, C-reactive protein (CRP), smoking status and sex have all been linked
with an increased likelihood of adverse cardiovascular events [1–3]. Telomere
length (TL), although not used in clinical practice, is one such parameter that has
repeatedly been linked with cardiovascular health and disease development [4].
Telomeres are the nucleotide-protein complexes that shield the chromosomal
ends from erosion caused by the end-replication problem during cell division and
distinguishes them from double-stranded breaks to prevent chromosomal fusion
[5]. Throughout the replicative lifespan of cells, their TL will decrease until a
critical threshold is reached. Critically short telomeres will typically lead to a cell
crisis resulting in senescence, apoptosis or immortalization [6]. TL is of particular
interest because it potentially provides a cumulative measurement of stresses
throughout life representing ‘‘biological age’’ [4].
Although there is still uncertainty about the mechanism(s) by which telomere
biology and CVD pathogenesis affect each other, results from both molecular
biology and epidemiology have repeatedly shown significant associations [7–11].
The same is true for cardiovascular risk factors such as insulin resistance,
hypertension [12], smoking status [13], oxidative stress and inflammation [14].
Systemic TL has also been linked to LV structure and function but mostly in
smaller, patient-specific settings and not in a general population [15–22]. Shorter
TL can be found in heart failure (HF) patients [23, 24] and patients suffering from
chronic HF have an increased morbidity if their telomeres are shorter [25].
However, reports on the association between TL and indicators of diastolic
dysfunction show conflicting results [18, 19]. Similarly, a positive correlation has
been described between LVM and PBL TL [20–22], but other studies did not
detect a significant association between TL and LVM index or LV hypertrophy
[18, 26, 27].
The population-based Asklepios Study offers the advantages of a large sample
size and the measurement of numerous potential confounders of TL and CVD.
We therefore investigated the relations between systemic TL and proven
prognostic parameters [28–32] of vascular stiffness, cardiac stiffness, systolic
Asklepios Telomere Length and Cardiovascular Stiffness
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function, diastolic function and ventricular mass, to shed light on the baseline
state of these correlations.
Methods
Study Population
All data presented in this paper were collected during the first round of the
Asklepios study on successful (cardiovascular) aging. The study comprises 2524
subjects approximately 35 to 55 years of age, free from overt cardiovascular
disease or other significant pathologies at baseline. The full description of the
study design, inclusion criteria, detailed methodology and population baseline
characteristics have been published previously [33]. The study was conducted in
concordance with the principles of the Declaration of Helsinki. All patients gave
written informed consent and the study was approved by the Ghent University
Ethical Committee. For the analyses reported here, we used the subset of 2509
patients for which reliable TL and all major TL confounder measurements (age,
sex, paternal age at birth) were available (cf. De Meyer et al. [34]).
Biochemical analyses
All subjects were fasting, had refrained from smoking for at least 6 hours and were
screened for active infection/inflammation before blood sampling. Conventional
serum parameters were measured using commercial reagents according to the
manufacturers’ recommendations on a Modular P automated system (Roche
Diagnostics, Mannheim, Germany), in an ISO 9002 certified reference laboratory
[33]. Coefficient of variation of all tests was ,3.0%. These parameters included
Interleukin-6 (IL-6), C-reactive protein (CRP), oxidized low-density lipoprotein
(ox-LDL), serum uric acid concentrations and brain natriuretic peptide precursor
[33].
Telomere Length
For TL-analyses, whole blood was collected in EDTA tubes cooled to 4 C˚. DNA
isolation was performed within 3 days of collection using the Puregene Genomic
Purification Kit (Gentra Systems, Minnesota, USA). The DNA was long term
stored at 280 C˚ before TL measurement in duplicate. 5 mg was digested with 5U
RsaI and 10U HinfI followed by gel electrophoresis, Southern blotting, radioactive
hybridization of the telomeric fragments and weight markers, phospho-imaging
and quantification (expressed as kbp: kilo base pairs) [14].
Echocardiographic and vascular examination
Blood pressure was recorded using bilateral triplicate measurements (1 min
intervals) on a rested, sitting subject using a validated oscillometric Omron HEM
device (Omron Healthcare Co. Ltd., Kyoto, Japan). Blood pressure values of these
Asklepios Telomere Length and Cardiovascular Stiffness
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six readings were averaged and the mean value of systolic blood pressure (SBP) is
used throughout this study. The subjects underwent a resting echocardiographic
examination and a scan of the left and right carotid and femoral arteries (VIVID
7, GE Vingmed Ultrasound, Horten, Norway). Left ventricular (LV) internal
dimensions were measured at end-diastole (LVEDD) with the area-length
method. Sphericity was defined as LV width divided by LV length and is expressed
as a percentage. Standard 2-D volumetric methods were used to calculate ejection
fraction (EF) from end-diastolic and end-systolic LV volumes and to calculate LV
mass (LVM). The LVM was scaled allometrically following the recommendations
of Chirinos et al. [35] as LVM/(Height)1.7 to account for the effects of both
obesity and blood pressure on LVM. We also scaled LVM to the body surface area
(g/m2) [36].
Other cardiac and arterial measurements included the following: systolic (s9),
and early (e9) and late (a9) diastolic septal mitral annulus pulsed wave tissue
Doppler (TDI) velocities, pulsed wave Doppler early (E) and late (A) diastolic
transmitral flow velocities, E-wave propagation velocity (Vpe) and carotid-
femoral pulse wave velocity (PWV). PWV was calculated as follows:
PWV~
DLS{F{DLS{C
DTQ{F{DTQ{C
m
s
h i
ð1Þ
In formula (1) DLS-F and DLS-C are the distances measured from sternal notch to
femoral and carotid measuring sites respectively, DTQ-F and DTQ-C are the time
delays between the start of the QRS complex and the onset of systolic flow in the
femoral and carotid artery measured by pulse wave Doppler imaging (full
methodology described in the online supplements of Rietzschel et al. [33]). CW
Doppler recordings were used to measure isovolumic relaxation time (IVRT) as
the interval from the closure spike of the aortic valve to onset of mitral flow.
Data analysis
Statistical analyses were performed in R 2.15.2. Continuous variables are reported
as the mean value ¡ standard deviation. Means of groups were compared with
Student (homoscedasticity) or Welch t-test (heteroscedasticity) as appropriate. To
evaluate the contribution of the different confounders to the response variables
under study we applied general linear models as implemented in the ‘glm’
function. We report both P-values and the estimated unstandardized effect sizes
(b) for TL in these models.
Results
Baseline characteristics of the population are presented in Table 1.
Asklepios Telomere Length and Cardiovascular Stiffness
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Diastolic function
Unadjusted models yielded positive linear associations between TL and E/A, e9/a9
(Fig. 1) and E/e9 (Table 2, Model 1). In successive (general linear) models, known
major confounders of diastolic function were added, i.e. age and sex in Model 2,
additionally heart rate (HR), systolic blood pressure (SBP) including use of
antihypertensive drugs and body mass index (BMI) in Model 3. We did not
remove non-significant independent variables from the proposed models in
Table 2 for the individual response variables as removal of the non-significant
terms did not alter the significance of the TL component. Addition of further
Table 1. Baseline characteristics of the Asklepios study population.
Variable Women (n51291) Men (n51218) P-valuea Population (n52509)
Age (years) 45.9¡6.0 46.1¡5.9 0.316 46.0¡6.0
Weight (kg) 66.7¡12.7 82.0¡12.4 ,2.2E-16 74.1¡14.7
Height (cm) 163¡6 176¡7 ,2.2E-16b 169¡9
Body Mass Index (kg/m2) 25.1¡4.6 26.5¡3.7 ,2.2E-16b 25.8¡4.3
Systolic Blood Pressure (mmHg) 123¡14 131¡13 ,2.2E-16b 127¡14
Pulse Pressure (mmHg) 45.5¡9.1 48.3¡7.4 ,2.2E-16b 46.9¡8.4
Pulse Wave Velocity (m/s) 6.60¡1.45 6.65¡1.46 0.397 6.62¡1.45
Heart Rate (min21) 67.2¡9.5 64.0¡10.7 6.01E-15b 65.6¡10.2
Used Antihypertensive Drugs 145 (11.2%) 118 (9.69%) 0.284c 263 (10.5%)
PBL TL (kbp) 7.96¡0.73 7.78¡0.71 3.26E-09 7.87¡0.73
E (cm/s) 78.9¡14.2 70.6¡13.0 ,2.2E-16b 74.9¡14.2
A (cm/s) 63.5¡11.9 59.6¡10.9 ,2.2E-16b 61.6¡11.6
e9 (cm/s) 9.41¡2.13 8.63¡1.83 ,2.2E-16b 9.03¡2.03
a9 (cm/s) 8.67¡1.55 9.23¡1.46 ,2.2E-16 8.94¡1.53
E/A 1.29¡0.32 1.22¡0.29 2.65E-7b 1.25¡0.31
e9/a9 1.13¡0.36 0.970¡0.29 ,2.2E-16b 1.05¡0.34
E/e9 8.68¡1.99 8.41¡1.78 3.36E-4b 8.55¡1.90
s9 (cm/s) 7.91¡1.13 7.93¡1.20 0.756 7.92¡1.16
Vpe (m/s) 79.4¡22.1 71.9¡19.5 ,2.2E-16d 75.7¡21.2
DT (ms) 167¡29 170¡30 9.29E-4 168¡30
Isovolumic Relaxation Time (ms) 81.8¡13.8 90.2¡12.9 ,2.2E-16 85.9¡14.0
LV Ejection Fraction (%) 64.8¡6.7 62.5¡6.4 ,2.2E-16 63.7¡6.7
LVEDD (mm) 44.9¡3.9 49.4¡4.4 ,2.2E-16b 47.1¡4.7
Sphericity (%) 56.9¡6.4 57.2¡6.5 0.246 57.0¡6.4
Left Ventricular Mass (g) 124¡31 179¡40 ,2.2E-16b 151¡45
LVM index (g/m‘1.7) 54.2¡13 69.0¡15.0 ,2.2E-16b 61.3¡15.9
NTproBNP (pg/ml) 81.3¡64.1 36.4¡39.2 ,2.2E-16bd 59.5¡58.0
a: P-value for comparison between sexes using independent t-test (b:unequal variance) or chi-square test (c).
d: Data was log transformed before statistical testing.
LVM: allometrically scaled Left Ventricular Mass index, PBL TL: Periferal Blood Leukocyte Telomere Length, E & A: peak transmitral flow velocities during
early (E) and late (A) diastolic filling, e9 & a9: peak movement speed of mitral annulus during early (e9) and late (a9) diastolic filling, DT: transmitral
Deceleration Time, NTproBNP: N-terminal prohormone of brain natriuretic peptide, LVEDD: Left Ventricular End-Diastolic Diameter, s9: peak systolic mitral
annulus movement speed, Vpe: pulse propagation velocity in early diastole.
doi:10.1371/journal.pone.0115071.t001
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potential confounders: LV sphericity, oxidative stress (oxidized-LDL cholesterol,
serum uric acid) or inflammatory markers (high-sensitive CRP, IL-6), did not
significantly alter the TL - diastolic dysfunction relationships when added to
Model 3 as an independent variable (data not shown).
In all models the positive association between E/A and TL remained significant
(see Table 2, P#0.002) with Model 3 accounting for approximately 43.2% of E/A
variability (2.64% of the total variability could be attributed to TL). Examining
the data separately by sex, we found that, upon adjustment for confounders
(Model 3), the association between E/A and TL was significant in both women
(b50.030, P50.001) and men (b50.023, P50.014). A similar approach was
adopted for the e9/a9 ratio. Results of the linear models were included in Table 2
and demonstrated significance of the adjusted associations for e9/a9 (Model 3:
b50.018, P50.012). Looking at both sexes separately, TL was a significant
independent variable in women (b50.022, P50.032), but only borderline in men
(b50.016, P50.098).
We further examined the components of these ratios (E/A and e9/a9) separately
to determine whether the associations were attributable to one of both
components or whether the ratios contained additional information beyond the
terms they consist of. Surprisingly, the results indicated that neither E (b50.226,
P50.535) nor e9 (b50.043, P50.341) were correlated with TL (Model 3). There
was however a correlation of TL with A (b520.905, P,0.001) and a9 (b520.079,
P50.040).
Fig. 1. TL, E/A. Scatterplot showing the unadjusted correlation between telomere length (TL) and the ratio of
early (E) over late (A) mitral annulus movement speed (red) and the regression line (black).
doi:10.1371/journal.pone.0115071.g001
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Accordingly, E/e9 was not correlated upon adequate adjustment (Model 3:
b50.014, P50.775), neither were other indices of diastolic function: flow
propagation velocity of the E-wave (Vpe; b50.212, P50.718), mitral inflow
deceleration time (b520.302, P50.712) or duration of the atrial contraction
(b520.028, P50.938). Only IVRT was inversely correlated with PBL TL (Fig. 2,
Model 3: b520.900, P50.011). IVRT was also inversely correlated with PBL TL
after age, sex and paternal-age adjustment (PBL TL as dependent variable;
Table 2. The association of TL (kbp) with different parameters of cardiovascular function using general linear models.
Response variable (RV) Model 1 Model 2 Model 3
E/A b 0.0696 0.0249 0.0264
P 2.83E-16 1.25E-03 8.09E-05
e9/a9 b 0.0764 0.0178 0.0182
P ,2.2e-16 0.0281 0.0120
E (cm/s) b 1.91 0.195 0.226
P 1.09E-06 0.600 0.535
A (cm/s) b 21.60 20.860 20.905
P 5.37E-07 4.62E-03 4.51E-04
e9 (cm/s) b 0.397 0.050 0.043
P 8.93E-13 0.304 0.341
a9 (cm/s) b 20.211 20.068 20.079
P 5.77E-07 0.100 0.0403
E/e9 b 20.158 20.0214 20.0124
P 2.62E-3 0.677 0.794
DT (ms) b 21.86 20.123 20.302
P 2.24E-02 0.881 0.712
IVRT (s) b 22.70 20.941 20.900
P 2.32E-12 9.25E-03 0.0115
log(NTproBNP (pg/ml)) b 0.017 20.004 20.005
P 0.119 0.657 0.617
LVM index (g/m1.7) b 22.37 20.194 0.0228
P 5.41E-08 0.616 0.943
LVEDD (mm) b 20.497 20.164 20.124
P 1.11E-04 0.158 0.261
EF (%) b 0.0216 20,0183 0.0156
P 0.906 0.922 0.933
s9 (cm/s) b 0.018 20.033 20.038
P 0.579 0.315 0.238
Model 1: RV , TL.
Model 2: RV , TL+Age+Sex.
Model 3: Model 2+Systolic BP+Heart Rate+BMI+Used Antihypertensive Drugs.
E & A: peak transmitral flow velocities during early (E) and late (A) diastolic filling, e9 & a9: peak movement speed of mitral annulus during early (e9) and late
(a9) diastolic filling, DT: transmitral Deceleration Time, IVRT: Isovolumic Relaxation Time, NTproBNP: N-terminal prohormone of brain natriuretic peptide,
LVM: allometrically scaled Left Ventricular Mass index, LVEDD: Left Ventricular End-Diastolic Diameter, EF: Ejected Fraction of end-diastolic volume, s9:
peak systolic mitral annulus movement speed, b: effect size (unstandardized), P: P-value of TL component.
doi:10.1371/journal.pone.0115071.t002
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b522.92E-3, P50.010). Additionally, we found no significant association with
brain natriuretic peptide (log(NT-proBNP): b520.005, P50.617) upon adjust-
ment.
Systolic function and LV structure
We could not document significant associations between TL and systolic function
after adequate adjustment (Model 3, EF: b50.016, P50.933 and s9: b520.038,
P50.238). Similarly no associations were found with LV structure assessed by LV
end-diastolic diameter (LVEDD: b520.124, P50.261) and LV mass (b520.214,
P50.801), body surface area adjusted LV mass (b50.010, P50.981) or
allometrically height-adjusted LV mass (b50.023, P50.943).
Arterial stiffness
No significant partial correlation was found between PWV and age-adjusted TL
(cf. supra), a result that remained unchanged after additional adjustments (Model
3, b520.001, P50.971). The same is true for pulse pressure (PP) in the Asklepios
population (Model 3, b5255E-6, P50.999).
Fig. 2. TL , IVRT. Scatterplot showing the unadjusted correlation between telomere length (TL) and
isovolumic relaxation time (IVRT) (red) and the regression line (black).
doi:10.1371/journal.pone.0115071.g002
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Discussion
Our main finding is that we can extend a number of previously described
associations between PBL TL and cardiovascular structure and function –usually
detected in smaller, diseased cohorts - towards a middle-aged, apparently healthy
population. After adjustment for confounders, we could not document an
association with systolic function, cardiac structure or vascular stiffness. We do
however document an intriguing association with certain parameters of LV filling.
LV filling and diastolic function
As mentioned in the introduction, previous reports on the association between TL
and indicators of diastolic dysfunction have led to apparently conflicting results.
Quartiles of telomere length were shown to correlate with diastolic dysfunction in
CAD patients (evaluated by E/A and pulmonary vein flow) [18]. In contrast both
E/A-ratio and diastolic dysfunction were not correlated with PBL TL in a study of
elderly subjects (.85 years) [19]. This can potentially be explained by the very
different nature of the populations under study. Our data showed a significant
association between PBL TL and both the E/A-ratio and the e9/a9-ratio and with
IVRT [37], but not with the E/e9-ratio (see Table 2 for details). E/e9 is mainly used
as an indicator of elevated filling pressures, reflecting more advanced diastolic
dysfunction not likely to be present in healthy subjects [38]. Concurrently, NT-
proBNP, a biochemical marker reflecting elevated filling pressure and diastolic
dysfunction [39], was not associated with PBL TL after correction for confounders
(Model 3).
Analysis of the terms constituting the E/A and e9/a9 ratios in this population
suggests that TL was associated with atrial contraction (A and a9), rather than with
parameters that could reflect myocardial relaxation or filling pressure, such as E
and e9, or reflect myocardial stiffness, such as shortened mitral deceleration time
[40]. As previous publications only described correlations with E/A but not with
the individual components, we cannot tell whether this was the case in other study
populations.
Relaxation and stiffness induce opposite effects on mitral E and A and hence on
E/A [40]. The present data do not provide sufficient evidence for an independent
association between PBL TL and LV relaxation or LV stiffness in the general
middle-aged population. Although there is an association with longer IVRT after
correction for heart rate and blood pressure, it is difficult to attribute this to
myocardial relaxation without a persisting association with the best validated
determinants e9 and Vpe [41]. The persisting associations with atrial contraction
flow velocity (A) and with the simultaneously occurring annular velocity (a9) then
most likely affects compound measures such as E/A and e9/a9. One could speculate
that increased IVRT and enhanced atrial contraction represent an early and subtle
delay of myocardial relaxation, which is not yet apparent in other measurements.
We therefore would describe the findings as correlation between PBL TL and
altered filling pattern without sufficient evidence for diastolic dysfunction. It is
Asklepios Telomere Length and Cardiovascular Stiffness
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noteworthy though that the associations with PBL TL were stronger in women
than in men, an interesting finding in light of the increased occurrence of diastolic
HF in women [42].
LV systolic function, structure and vascular stiffness
In this population without overt cardiac disease, we report that PBL TL was not
associated with minor changes in systolic parameters such as EF and tissue
Doppler movement speed of the septal mitral annulus (s9). Increased LV mass
correlates with increased all-cause and cardiovascular mortality [43] and a
positive correlation has been described between LVM and PBL TL [20–22].
However, our findings do not support an association between PBL TL and LVM,
body surface area scaled LVM or height-scaled LVM in the context of a relatively
young population. Two other studies also failed to detect an association between
TL and LVM index or LV hypertrophy in two older populations (,65 years)
[18, 26]. These findings and the fact that the former studies do not agree on
whether normotensive or hypertensive patients show a TL – LVM correlation,
lead us to the conclusion that there is likely an as of yet unidentified confounder
at work. A third study found no cross-sectional or longitudinal associations
between PBL LTL and cardiac measurements including LVM (adjusted for body
surface area) [27].
With respect to vascular stiffness, no significant associations between PWV (or
PP) and TL were found in either sex. Previous studies have reported this
association to be significant in men [15, 44]. The discordance may be attributable
to age and health characteristics of the respective populations. Indeed these
populations were featured by a higher mean age (,10 years) and a higher mean
PWV (60% higher) compared to the Asklepios study albeit with a different
measurement protocol for PWV.
Limitations
The Asklepios data set does not yet include any longitudinal information thus
limiting it to all the drawbacks associated with cross-sectional study designs.
Particularly claims of causality can not be made with cross-sectional data alone.
Despite the extensive characterization of the Asklepios study, there are some
descriptors of CV function which were not measured (e.g. pulmonary venous
flow). We cannot exclude the involvement of these factors.
Mechanistic insights
There are two general models in which TL is tied to cardiovascular health. The
first states that telomere shortening is a primary driver of (cardiovascular) ageing.
In support of this model our findings indicate that the associations between some
parameters of LV filling and telomere length, are not limited to (chronic) HF
patients, but may already be present in a young to middle-aged, apparently
Asklepios Telomere Length and Cardiovascular Stiffness
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healthy population and are more pronounced in women. It is tempting to
speculate that telomere biology could be mechanistically involved in the early
pathogenesis of diastolic dysfunction and possibly HF by extension. As a matter of
fact, in mice, knock-out of the telomere elongating enzyme telomerase, resulted in
shortened telomere length over several generations which was associated with the
development of overt chronic HF [45]. However, telomere biology in mice cannot
be easily transposed to humans and additional experiments would be absolutely
necessary to pinpoint the exact mechanisms.
In our data, TL was clearly correlated with E/A, e9/a9 and IVRT but not with
other indices of diastolic function. We further explored the relationship between
PBL TL and other cardiac and hemodynamic parameters such as sphericity of the
ventricle, Vpe, duration of the A-wave and deceleration time (data not shown).
No significant associations were found that could help provide clues as to the
mechanism by which PBL TL and diastolic function might be linked.
The second model states that TL is merely an epiphenomenon, an indicator
influenced by conditions in the ageing body. Accelerated telomere attrition in
subjects with mildly impaired diastolic function could also be caused by oxidative
stress and inflammation, two factors that are known to affect diastolic function as
well as telomere length [14, 23, 46–48]. In this case it might be expected that the
addition of oxidative stress and inflammation would cause reduced significance
for TL. However, additional markers (CRP, oxidized LDL, IL-6 and serum uric
acid) did not substantially alter the significance of the PBL TL component relative
to Model 3 in Table 2 (data not shown). It should be noted though that these
markers only reflect point measurements of oxidative stress and inflammation,
which are variable by nature, whereas telomere length has been hypothesized to
reflect their cumulated effects (reviewed in De Meyer et al. [4]).
Our data, at present, is insufficient to determine the more likely model. Some of
the non-replicated associations might still become apparent with ageing, assuming
that a certain threshold of telomere attrition needs to be reached before it has a
measurable effect on cardiovascular stiffness or visa versa.
Conclusions
Our results show that several parameters of cardiovascular structure and function
which have been associated with TL, fail to replicate in a well-phenotyped middle-
aged population sample. However, PBL TL is associated with subtle changes in
certain parameters of LV filling in this population and these associations are more
apparent in women. Further investigation of the underlying biological mechan-
isms is warranted to provide insights into the relationship between PBL TL,
diastolic function and cardiovascular health.
Asklepios Telomere Length and Cardiovascular Stiffness
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